El-Khouly et al. conducted a phase I/II trial to determine the safety, tolerability, and efficacy of bevacizumab, a VEGF inhibitor, irinotecan, a topoisomerase I inhibitor, and Erlotinib, an EGFR inhibitor, among 9 patients with progressive DIPG. This evidence concerns the gene VEGFA and diffuse intrinsic pontine glioma.